Literature DB >> 2845872

Interleukin-2 initiates metabolic responses associated with critical illness in humans.

H R Michie1, T J Eberlein, D R Spriggs, K R Manogue, A Cerami, D W Wilmore.   

Abstract

The cytokine interleukin-2 is a primary modulator of the immune response that occurs after infection, trauma, and transplant rejection, yet its role as a mediator of associated metabolic changes in surgical illness is unknown. We studied clinical and metabolic responses in eleven tumor-bearing humans with normal renal and hepatic function receiving bolus intravenous (I.V.) interleukin-2 (30,000 U/kg). Additional subjects (n = 6) were pretreated with the cyclooxygenase inhibitor, ibuprofen (1600 mg, orally), before interleukin-2 administration. Serial measurements were made of vital signs, symptoms, hematology, and plasma concentrations of pituitary and stress hormones and selected cytokines. Administration of interleukin-2 resulted in fever, tachyacardia, "flu-like" symptoms, and neurohormonal elaboration. The responses observed were quantitatively similar to those that occurred after endotoxin administration in healthy subjects (n = 13), but differed in the following manner: 1) the onset of fever and endocrine changes occurred after a longer latent interval (180-240 minutes vs. 60-90 minutes after endotoxin), 2) peak responses after the administration of interleukin-2 also occurred later, 3) no increased circulating tumor necrosis factor was detected after administration of interleukin-2 (peak plasma concentration was greater than 35 pg/ml vs. 270 +/- 70 pg/ml after endotoxin administration), and 4) administration of interleukin-2 but not of endotoxin was associated with increased circulating concentrations of gamma interferon (peak plasma concentration 1.7 +/- 0.2 NIH U/ml vs. less than 0.1 NIH U/ml after endotoxin administration). Fever and neurohormonal responses after interleukin-2 administration were greatly attenuated by ibuprofen administration. Interleukin-2 induces other cytokines that exert their effects largely through the cyclooxygenase pathway. Interleukin-2 may be an important signal, initiating the integrated host responses to infection and injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845872      PMCID: PMC1493748          DOI: 10.1097/00000658-198810000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  32 in total

Review 1.  Lymphokines.

Authors:  C A Dinarello; J W Mier
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Effects of infection on oxygen consumption and core temperature in experimental thermal injury.

Authors:  L H Aulick; A T McManus; A D Mason; B A Pruitt
Journal:  Ann Surg       Date:  1986-07       Impact factor: 12.969

3.  Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma.

Authors:  V Ruggiero; J Tavernier; W Fiers; C Baglioni
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

4.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

Authors:  I C Kettelhut; W Fiers; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  The induction of interleukin-1 in humans and its metabolic effects.

Authors:  J M Watters; P Q Bessey; C A Dinarello; S M Wolff; D W Wilmore
Journal:  Surgery       Date:  1985-08       Impact factor: 3.982

6.  Both inflammatory and endocrine mediators stimulate host responses to sepsis.

Authors:  J M Watters; P Q Bessey; C A Dinarello; S M Wolff; D W Wilmore
Journal:  Arch Surg       Date:  1986-02

7.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

Authors:  G E Nedwin; L P Svedersky; T S Bringman; M A Palladino; D V Goeddel
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  16 in total

Review 1.  The role of mediators in the response to thermal injury.

Authors:  Y K Youn; C LaLonde; R Demling
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

2.  Posttraumatic skeletal muscle proteolysis: the role of the hormonal environment.

Authors:  P Q Bessey; Z M Jiang; D J Johnson; R J Smith; D W Wilmore
Journal:  World J Surg       Date:  1989 Jul-Aug       Impact factor: 3.352

Review 3.  Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.

Authors:  J Fukata; H Imura; K Nakao
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

4.  Effects of total intravenous anesthesia with propofol on immuno-endocrine changes during surgical stress.

Authors:  Tetsuhiro Sakai; David O'Flaherty; Adolf H Giesecke; Akira Kudo; Kazuyoshi Hirota; Akitomo Matsuki
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

5.  Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2.

Authors:  R Welbourn; G Goldman; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

6.  Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Authors:  A Schomburg; H Kirchner; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.

Authors:  J S Economou; M Hoban; J D Lee; R Essner; S Swisher; W McBride; D B Hoon; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans.

Authors:  M L Rodrick; N M Moss; J T Grbic; A Revhaug; S T O'Dwyer; H R Michie; D B Gough; D Dubravec; J M Manson; I B Saporoschetz
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

10.  Immunosuppression follows systemic T lymphocyte activation in the burn patient.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; G B Mills; W J Peters
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.